Paclitaxel Coated-PTCA Ballon Catheter
TransPax™ DCB Coating Efficacy study2 by Dr. Granada
• 14 days following that injury, the swine was treated with a with a TransPax balloon, a Medtronic In.Pact™ DCB, a Bard Lutonix™ DCB and POBA, and Boston Scientific’s Sterling™ PTA balloon.
• Angiography was captured pre‐injury, at treatment, and 28 days post-treatment.
• There were no statistical differences between Drug-Coated Balloon types2
• Result support clinical efficacy of TransPax™ coating2
Presence of Paclitaxel (PTx) Post AGENT™ Treatment4 by CVPath Institute
• Demonstrates drug transfer and drug distribution post Agent treatment in a rabbit model, using confocal microscopy to assess paclitaxel distribution after treatment by AGENT DCB.
• Endothelialization is recovering from complete absence 15 minutes after DCB deployment to 14 days, where presence of CD31 positive cell junctions is observed4.
Presence of Paclitaxel from 15 minutes to 14 days post balloon deployment
|15 Minutes||1 Day||3 Days||7 Days||14 Days|
AGENT DCB: Drug efficiently into the vessel’s wall
- This animal model investigated the efficacy of drug delivery after deployment of drugcoated balloons using the TransPax paclitaxel coating system
- Simultaneous staining for CD31 and paclitaxel were successfully used to co-localize drug in relation to endothelial cells and to characterize dynamic changes in localization over time during healing
- CD31 expression by endothelial cells was lowest at 15 minutes (2.86 mm2) and increased up to 14 days (57.04 mm2). This showed the healing process